Seamless interlinking: How risk management and clinical evaluation go hand in hand

In this blog post you will learn how to transfer identified hazards from risk management to targeted clinical issues, which regulatory requirements of the MDR and relevant ISO standards you have to consider, how to link the benefit-risk analyzes with clinical evidence and derive the clinical data requirement-from the risk management acts to clinical evaluation Report - for a complete traceability are essential, which practice -oriented approaches and best practices promote smooth interdisciplinary cooperation, how they recognize and bypass typical stumbling blocks at an early stage and what outlook there are on further interfaces in product development and post -market surveillance.

Abbreviations

MDR	Medical Device Regulation (EU Ordinance 2017/745)
Sota	State of the Art (state of the art)
CEP	Clinical evaluation plan
CERIUM	Clinical Evaluation Report
Pmcf	Post-Market Clinical Follow-up
Pms	Post-Market Surveillance

Underlying regulations and norms

EU Regulation 2017/745 (MDR)

En ISO 14971

1 Introduction

The tightened requirements of the MDR make a close integration of all processes essential. In particular, the interface between risk management and clinical evaluation plays a crucial role: Only if identified risks are consistently transferred to clinical issues, reliable benefit -risk analyzes can be created and the actual data requirement for the CLINical Evaluation Report (CER) can be derived precisely.

2. Basic terms and process overview

2.1 Definition of Risk Management
Risk management is a systematic, documented, and ongoing cycle for identifying, assessing, controlling, and monitoring risks that may arise from a medical device. It encompasses all potential hazards throughout the entire product lifecycle – from development and manufacturing to use and disposal. According to ISO 14971, the process includes risk analysis (identifying and assessing the severity and probability of occurrence), risk assessment (determining acceptable risk levels), risk control (defining and implementing measures), and verifying the effectiveness of these measures. All steps are documented in the risk management file and regularly updated through reviews and change control processes.

2.2 Definition of Clinical Evaluation
Clinical evaluation is an interdisciplinary process that systematically compiles and evaluates all available clinical data on the medical device and draws conclusions regarding its safety and performance. It forms a central interface with numerous other processes, such as design verification, usability, post-market surveillance, and vigilance. The aim is to demonstrate, through a structured benefit-risk analysis, that the expected benefits of the product clearly outweigh the remaining risks. The results are documented in the Clinical Evaluation Report (CER) and serve as key evidence for notified bodies and regulatory authorities.

2.3 Process map: From risk analysis to clinical evaluation
The transition from risk management to clinical evaluation can be divided into three phases:

1. Risk analysis and prioritization
• Identification of hazards: Systematic recording of all potential risks along the product life cycle (design, production, application, disposal).
• Severe grade and occurrence: Assessment of how serious damage would be and how likely his appearance is.
2. Derivation of clinical issues
• Risk -to -evidence mapping: Every risk classified as critically is translated into one or more clinical questions. Example: A high risk of thrombosis in an implantable device leads to the question of whether the thrombosis rate in clinical studies falls below acceptable limit values.
• Determination of the data requirement: What type of clinical data (e.g. study data, registry analyzes, real -world -evidence) are needed to reliably evaluate the risk?
3. Integration into the clinical evaluation
• Benefit -Risk analysis: merging of the risk assessment with the clinical benefit; Representation that the expected benefit predominates the remaining risks by far.
• Documentation in the CER: Structured proof that all identified risks were addressed and occupied by clinical evidence. Cross -references to risk management clocks ensure traceability.

This process map makes it clear that risk management and clinical evaluation are not isolated disciplines, but contribute closely to the common goal: the market approval of a secure and effective medical device.

3. Interface: Risk management → clinical evaluation

3.1 Derivation of the claims for clinical security from clinically relevant risks

What are clinically relevant risks?

Clinically relevant risks are the potential hazards that can affect health, security or well -being of patients directly and specifically (e.g. tissue damage, infection ...).

Proceed

Every risk identified in risk management is first recorded in the risk analysis and evaluated in terms of severity and probability of appearance.

Clinically relevant risks identified in risk management are systematically translated into verifiable clinical questions. Clinically relevant risks from the risk analysis should be addressed by one or more clinical safety claims/endpoints.

In essence, it is about systematically transferring clinically relevant risks from the risk management acts to the clinical evaluation and providing clinical evidence there. The process is divided into four steps:

a) Identification of clinically relevant residual risks
: The risk management file lists all potential harms that could concretely threaten the patient (e.g., tissue trauma, infection, false alarm, data loss). These residual risks form the basis for the clinical assessment.

b) Translation into clinical endpoints
For each residual risk, one or more measurable endpoints are defined and recorded in the Clinical Evaluation Plan (CEP). An endpoint precisely describes how the respective risk is objectively measured (e.g., incidence rate of irritation, percentage of cleaning cycles performed without microbial detection, number of false alarms per 100 hours of operation).

c) Determining the evidence strategy
According to the three routes of clinical evaluation, select the appropriate data source:

1. Own clinical studies for direct, prospective data on the product
2. Equivalence or literature literature on comparable systems
3. Performance and in -vitro tests or PMCF if clinical studies are not suitable.
4. For each endpoint, you determine which study designs, sample circumference or test protocols are required to make valid statements.

d) Documentation and Benefit-Risk Analysis in the CER
– Tabular Overview: Compile the endpoints, data sources, and main results in a structured table format.
– Narrative Sections: Explain how the results achieved minimize the respective residual risk.
– Benefit-Risk Table: Clearly demonstrate that the expected clinical benefit significantly outweighs the remaining risks.
– Traceability: In each CER section, reference the corresponding risk in the risk management file to ensure complete traceability.

This procedure ensures that every risk management defined in risk management systematically addressed, documented with a suitable evidence and evaluated positively in the benefit -risk ratio. This forms the basis for convincing admission documentation and long -term patient safety.

3.2 Linking Benefit/Risk Analysis with Clinical Evidence
The benefit/risk analysis forms the core of the Clinical Evaluation Report (CER) and links the residual risks defined in risk management with the data collected during the clinical evaluation. The aim is to demonstrate, through a systematic presentation, that the expected clinical benefit clearly outweighs the remaining risks.

4. Best practices

In order for the interlinking of risk management and clinical evaluation not only formally, but actually effectively, the following proven procedures have established themselves in everyday work:

4.1 Frequent stumbling blocks

1. Unclear questions:
   If clinically relevant risks are not precisely translated into clinical endpoints (clinical safety claims), the data requirements cannot be clearly determined. Avoid vague formulations.
2. Opaque Traceability:
   If clear cross-references do not exist in the CER and risk management file, auditors cannot trace the origin of the results. Focus on traceability from the outset.
3. Static documents:
   A risk management file or CER, once created, fails to achieve its purpose if it is not regularly updated. Even minor design modifications can introduce new risks or change data requirements.
4. Isolated solutions instead of interdisciplinary teams:
   When clinicians, engineers, and regulatory affairs professionals work separately, gaps arise. Plan interdisciplinary reviews with clearly defined responsibilities.
5. Inappropriate route selection:
   Choosing the wrong approach between in-house studies, equivalence data, or performance data leads to unnecessary effort or regulatory inquiries. Make the route decision early on, based on a transparent evaluation framework.

4.2 Continuous update

• Define change control triggers.
  Specify which changes (e.g., design updates) automatically trigger an update of risk management and CER.
• Regular review cycles:
  Schedule meetings of all stakeholders at least every six months to update risk assessments and clinical data. Use checklists to ensure no topics are overlooked.
• Using digital tools:
  Through automatically maintained cross-references, digital tools link clinically relevant risks with the associated clinical endpoints and the corresponding CER chapter sections. This ensures seamless traceability without manual effort, and auditors can check the entire evidence trail with just a few clicks.
• Establish documentation roles:
  Define clear roles for authors, reviewers, and approvers in both processes. Include metadata in documents, such as version, release date, and revision history.

4.3 Example: Derivation of end points/claims for clinical security from clinically relevant risks 

Imagine you have a digital infrared earmometer as a product in the product portfolio.

As part of the clinical evaluation of the thermometer, the following clinically relevant residual risks were identified from the risk management fact:

• Ear canal irritation or injury:
  Improper insertion of the probe can lead to pain, microtrauma or, in the worst case, eardrum injuries.
• Cross-contamination:
  Inadequate cleaning or a lack of disposable probe covers can promote the transmission of pathogens (e.g., otitis pathogens) between patients.
• Battery leakage / chemical exposure:
  Leaking battery fluid can cause skin irritation or burns if patients or caregivers come into contact with it.

Further procedure in the clinical evaluation:
From these risks, you derive one or more endpoints in the CEP (e.g., incidence of ear irritation, contamination rate of reused probe covers) and substantiate them with suitable evidence (studies, user usability tests, cleaning validations). This ensures that the benefit-risk ratio of your ear thermometer is clearly positive and guarantees safe use for patients.

From the clinically relevant risks found in risk management, z. B. the following quantifiable claims result:

• Ear canal irritation
  endpoint/measurable parameter:Incidence of ear irritation or microtrauma ≤ 0.1%
  → Claim: “Causes no irritation in ≥ 99.9% of cases (if this data was collected in the study(s))”
• Cross-contamination
  endpoint/measurable parameter:Contamination rate ≤ 1% after validated cleaning and disinfection protocol
  → Claim: "Achieves a contamination rate of ≤ 1% when using the validated cleaning and disinfection procedure." (Data from studies/product register)

Or a common end point/claim would also be possible:

• Safe clinical use with a minimal incidence of adverse events– achieved through compliance with EN ISO 109931 (Biological Safety), IEC 60601-1 and IEC 60601-1-2 (Electrical Safety), and IEC 62366-1 (Usability):
  – Incidence of ≤ 0.1% of minor ear irritation
  – Contamination rate of ≤ 1% after a validated cleaning/disinfection protocol
  – Documented cases of battery leakage in customer feedback = 0

5. Conclusion

A consistently networked procedure for risk management and clinical evaluation is the key to an efficient and regulatory correct market launch of medical devices. By specifically transferring identified risks into clinical issues and systematically deriving the clinical data requirement, they create resilient foundations for benefit -risk analyzes and meaningful clinical claims. Regular updates, clear traceability and interdisciplinary cooperation prevent typical stumbling blocks and ensure that both developers and auditors recognize the common thread at all times. Use digital tools and defined change control trigger to keep your processes agile and to meet the growing requirements of the MDR. In this way, they not only lay the foundation for successful approval, but also strengthen the trust of users and named areas in the long term in the safety and performance of their products.

6. How we can help you

We would be happy to support you in making the interface between risk management and clinical evaluation efficiently:

• Gap analysis and audit readiness:
  We review your risk management file and clinical evaluation for completeness, traceability gaps and compliance (ISO 14971, MDR) and prepare you specifically for audits.
• “Risk-to-Clinic” Workshops:
  In interactive workshops, we jointly define clinically relevant residual risks, derive precise endpoints, and formulate quantifiable claims for clinical safety.
• Data Strategy & Route Decision Route Decision
  We advise you on the selection of the optimal data sources – your own studies, equivalence data or performance/PMCF tests – and support you in study planning or PMCF design.
• Regulatory support
  From the preparation of your notified bodies audits to the submission: We support you in document creation, review and follow-up.

Want to know more? Contact us for a free initial consultation!